

Taltz

Saudi Arabia · access guide

How to access Taltz from Saudi Arabia, the named-patient import pathway, 2026

By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23

A Saudi Arabia patient with moderate-to-severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, or non-radiographic axial spondyloarthritis may receive a prescription for Taltz (ixekizumab) from their treating dermatologist or rheumatologist. Taltz is FDA-approved in the United States and manufactured by Eli Lilly. It is a humanised IgG4 monoclonal antibody that selectively binds IL-17A, interrupting a central driver of psoriatic and axial spondyloarthritis inflammation. Where the indication, dose form, or specific product brand is not locally stocked, a named-patient import pathway via the Saudi Arabia Ministry of Health (MoH) is the legitimate route.

This guide explains the pathway, what documentation your physician needs, typical costs and timing, and where Reserve Meds fits in.

The clinical situation

Taltz is administered subcutaneously with an induction series, higher loading doses for psoriasis, a single loading dose for axial SpA and PsA, followed by maintenance every 4 weeks. Your treating physician confirms severity (PASI/BSA for psoriasis, BASDAI/ASDAS for axial SpA), TB and infection screening, and monitoring plan per FDA labeling.

Is Taltz legally importable into Saudi Arabia?

Yes, through the Saudi Arabia Ministry of Health Drug and Food Control (SFDA) named-patient framework. The pathway allows a Saudi Arabia-licensed physician to import a medicine not locally registered for the specific indication or dose form when: (a) the medicine is approved by a recognised reference authority (FDA qualifies), (b) no clinically equivalent registered alternative fits, (c) the physician takes clinical responsibility, and (d) chain of custody is documented.

IL-17 inhibitors are a familiar biologic class in Saudi Arabia dermatology and rheumatology. Named-patient imports are used where the specific product strength or patient-pen form is not stocked or where the indication lies outside the local registration envelope.

How the pathway works, step by step

1. **Consultation with your treating physician.** Severity documentation and clinical rationale.
2. **Pre-treatment screening.** TB, hepatitis, and infection screening per labeling.
3. **Saudi Arabia MoH named-patient application.** The physician or hospital pharmacy files the application.
4. **US-side sourcing.** Reserve Meds coordinates with our US-licensed specialty wholesale partner.
5. **Cold-chain shipment.** Taltz ships at 2-8°C with continuous temperature monitoring.
6. **Arrival and first dose.** The dispensing facility releases product for in-clinic or at-home administration after training.

What documentation your physician needs

Your physician will typically need to provide:

- Clinical rationale letter confirming diagnosis, severity, prior therapies, and Taltz as the indicated treatment
- Verification of their Saudi Arabia medical licence
- Patient identifier
- Pre-treatment screening confirmation
- Planned induction and maintenance regimen

Reserve Meds provides a physician documentation kit with the templates Saudi Arabia MoH reviewers expect to see for IL-17-class biologics, including the IBD vigilance note recommended for this class.

Costs and timing

Taltz's US cash-pay drug-only reference price for a single 80 mg pre-filled pen or auto-injector sits in a broad indicative range of roughly USD 6,500-7,500; full multi-dose induction regimens cost accordingly more in month one. International cold-chain logistics, Saudi Arabia MoH documentation handling, and concierge coordination add incremental cost. Reserve Meds issues a full transparent quote at the start of intake. Indicative range.

Indicative timing for first dose after cohort intake opens is 10-21 days from the moment a complete application is submitted. Maintenance doses ship on a rolling basis.

Fulfillment availability is limited to our first cohort, and all timelines published on this site are indicative. If your clinical situation is time-sensitive, tell us at intake. We triage accordingly.

Reserve Meds's role

Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. For Taltz specifically, we provide:

- **Sourcing.** Through our US-licensed specialty wholesale partner, operating under DSCSA chain-of-custody.
- **Documentation.** Regulatory package for your physician and for Saudi Arabia MoH review.
- **Logistics.** Cold-chain, temperature-monitored shipment.
- **Concierge case lead.** A named point of contact.

What we do not do: we are not the prescriber, we do not practise medicine, and we are not the dispensing pharmacy. All clinical decisions remain with your treating physician.

Frequently asked

Is this legal in Saudi Arabia? Yes, when executed through the Saudi Arabia MoH named-patient framework with appropriate documentation.

What if another IL-17 is locally available? Your physician will consider any locally registered alternative. Named-patient rationale applies where Taltz specifically fits your case.

Can Taltz be self-injected? Yes, the auto-injector and pre-filled pen are designed for patient or caregiver self-injection after clinic training.

Will private insurance cover this? Cash-pay is the default. Some Saudi Arabia insurers reimburse named-patient imports case by case; we supply documentation for your submission but do not process insurance claims directly.

Reserve Meds's role

US-based concierge coordinator for cross-border specialty medicine. We are not the prescriber, not the dispensing pharmacy, and not the manufacturer. All clinical decisions remain with your treating physician.

Reserve Meds

reserved for you.

Composite case examples. This document is for general information only and does not constitute medical advice. Please consult your treating physician.

Reserve Meds is in pre-launch. Published timelines and cost ranges are indicative, not guarantees.

reservemeds.com · hello@reservemeds.com